News

Number of news items returned: 201 to 220 records of 404

Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project, Rovina Project Shows Off Digital Reconstruction of the ARIS Priscilla Catacombs

08 December 2015

(12597 views)

"Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project.   Aerospace company GMV have been awarded ...

Australian Trading and Investment Corporation Investor Update

07 December 2015

(12162 views)

"To all interested parties, Since our last update there have been some exciting updates, as listed below:   ..Our model portfolio increased by ...

BioCube Corporation: A Promising Year End for BioCube

04 December 2015

(12583 views)

"This has been a busy and exciting few weeks for the team at BioCube Corporation. Commencing with an Austrade mission ...

BioCube Raising $3 Million

13 November 2015

(12571 views)

The Eco Investor website published the following article about BioCube on November 13th, 2015:   "The developer of a portable and community-sized ...

Funding Strategies Connect - November 2015

12 November 2015

(12051 views)

Dear Readers, Today it is my pleasure to introduce you to BioCube, Appee and China Dairy. Ocular Robotics and Opmantek have both ...

Pre-Christmas Networking Event Invitation

11 November 2015

(11308 views)

We are delighted to invite you  to a pre-Christmas networking event over drinks and canapes with the Funding Strategies &  ...

CRe8 Home & Finance: Close of offer – 18th December 2015

10 November 2015

(12007 views)

To Whom It May Concern: CRe8 has received a positive response from its offer with the following highlights:   Round 1 closed within ...

SEC Adopts Rules to Permit Crowdfunding

01 November 2015

(11877 views)

SEC Adopts Rules to Permit Crowdfunding - big news in the discussion around equity funding for emerging and growing companies! ...

Ocular Robotics Recognised as a Game Changer in Silicon Valley, and Media Interest in the Unique Capabilities of OCR’s 3D Scanners Grows with Articles from SPAR Point Group and Lidar News

26 October 2015

(11427 views)

"Ocular Robotics Recognised as a Game Changer in Silicon Valley. Ocular Robotics has been recognised as a game changer in the ...

Australian Trading and Investment Corporation update: New Team, New Home & Bigger Plans!

23 October 2015

(13441 views)

"Successfully launches a limited Convertible Note offering US Fund Manager and Australian Small Cap Equity Fund Manager join the Management Board The ...

Queensland Premier names Opmantek as Queensland's Leading ICT Exporter and Innovator

23 October 2015

(13175 views)

"Opmantek (ASSOB:OMK) has been acknowledged by Queensland Premier Annastacia Palaszczuk for innovation, leadership and for being QLD’s leading ICT exporter ...

Ocular Robotics Issues Supplementary Offer Document

19 October 2015

(12146 views)

"The Company has issued a Supplementary Offer Document, dated 17th October 2015 in order to provide investors with an update ...

CRe8 Home & Finance: Cornerstone $1m Investor and Trading Halt Update

15 October 2015

(12236 views)

"To Whom It May Concern: We are very pleased and excited to announce that CRe8 Home and Finance Ltd (CRe8) has ...

Opmantek (ASSOB:OMK) has been acknowledged by Queensland Premier Annastacia Palaszczuk

14 October 2015

(12883 views)

The NewsMaker website has published the following article about Opmantek, today October 14th, 2015:   "BRISBANE, QLD – Opmantek (ASSOB:OMK) has been ...

Policy Hack: Marketing of share offers under non-disclosure

10 October 2015

(12608 views)

Marketing of share offers under non-disclosure. The current regulations allow property and business for sale to be widely advertised and ...

Significant Commercial Agreement - Trading Halt CRe8 Home and Finance Limited (ASSOB: CHF)

08 October 2015

(12234 views)

"CRe8 has signed a significant commercial agreement, which in the Directors’ opinions materially enhances the value of the company. CRe8 ...

Ocular Robotics: Australian Robotics Company a Game Changer in Silicon Valley

28 September 2015

(14011 views)

  "Ocular Robotics has been recognised as a game changer in the global robotics revolution. The Next Generation Game Changer Award ...

Funding Strategies Connect - September 2015

24 September 2015

(11864 views)

Dear Readers, This month I am delighted to share updates from YDF, CRe8, ATIC, Mandala, Opmantek, Ocular Robotics and Squirel with ...

YDF Holdings reaches minimum subscription, launches on ASSOB's primary board

17 September 2015

(12870 views)

"Your Digital File (ASSOB: YDF) is thrilled to announce that the Company’s capital raise has reached minimum subscription and the ...

Squirel completes capital raising

16 September 2015

(13613 views)

"Squirel Ltd (“Squirel” or the “Company”) (ASSOB: SQU) is pleased to announce the suspension of it’s capital raising campaign and ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625